Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: Comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy

Annals of Nuclear Medicine

Volumn 22, Issue 5, 2008, Pages 395-401

  Takano, Akie ^a   Oriuchi, Noboru ^a   Tsushima, Yoshito ^a   Taketomi Takahashi, Ayako ^a   Nakajima, Takahito ^a   Arisaka, Yukiko ^a   Higuchi, Tetsuya ^a   Amanuma, Makoto ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

2 18F fluoro 2 deoxy D glucose positron emission tomography ( 18F FDG PET); 123I meta iodo benzyl guanidine ( 123I MIBG); Diffusion weighted magnetic resonance imaging (DWI MRI); Paraganglioma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; FLUORODEOXYGLUCOSE F 18;

ADRENAL SCINTISCANNING; ADULT; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; DRUG UPTAKE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

3-IODOBENZYLGUANIDINE; ADULT; AGED; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 46649111738     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-008-0128-1     Document Type: Article

References (16)

1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005;366:665-675.
2. Edström Elder E, Hjelm Skog AL, Höög A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 2003;29:278-283.
3. Lynn MD, Shapiro B, Sisson JC, Beierwaltes WH, Meyers LJ, Ackerman R, et al. Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology 1985;155:789-792.
4. 111In] octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-693.
5. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, et al. Comparison of somatostatin analog and metaiodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895-902.
6. Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y, et al. Present role and future prospect of positron emission tomography in clinical oncology. Cancer Sci 2006;97:1291-1297.
7. 18F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing's syndrome. Ann Nucl Med 2003;17:403-406.
8. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18] fluoro-2-deoxy-D-glucose PET. Radiology 1999;212:35-41.
9. Menzel C, Graichen S, Berner U, Risse JH, Diehl M, Dbert N, et al. Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET. Acta Med Austriaca 2003;30:37-40.
10. Ezuddin S, Fragkaki C. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy. Clin Nucl Med 2005;30:579-581.
11. Timmers HJLM, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 2007;25:2262-2269.
12. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004;22:275-282.
13. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188:1622-1635.
14. 18F] fluoro-D-glucose with computer control. Int J Appl Radiat Isot 1984;35:445-454.
15. Tsushima Y, Takano A, Taketomi-Takahashi A, Endo K. Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images. Acad Radiol 2007;14:643-650.
16. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 2007;21:209-215.